IDELALISIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H18FN7O
Molecular Weight	415.423
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC[C@H](NC1=NC=NC2=C1N=CN2)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4

InChI

InChIKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N

InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H18FN7O
Molecular Weight	415.423
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PI3-kinase p110-delta subunit 43	Antagonist 2,849		2.5 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Chronic lymphocytic leukemia 59	Primary	Approved 8,583	ZYDELIG
Follicular B-cell non-Hodgkin lymphoma (FL) 1	Primary	Approved 8,583	ZYDELIG
Small lymphocytic lymphoma 2	Primary	Approved 8,583	ZYDELIG

C_max

Value	Dose	Analyte	Population
2258.8 ng/mL	150 mg 2 times / day multiple, oral	IDELALISIB plasma	Homo sapiens
2647.5 ng/mL	150 mg single, oral	IDELALISIB plasma	Homo sapiens
1953 ng/mL	150 mg 2 times / day steady-state, oral	IDELALISIB plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
9293.39 ng*h/mL	150 mg 2 times / day multiple, oral	IDELALISIB plasma	Homo sapiens
9094.76 ng*h/mL	150 mg single, oral	IDELALISIB plasma	Homo sapiens
10439 ng × h/mL	150 mg 2 times / day steady-state, oral	IDELALISIB plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
8.2 h	150 mg 2 times / day steady-state, oral		IDELALISIB plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)	Other AEs: Diarrhea, Pneumonia...
150 mg 2 times / day steady, oral Recommended	unhealthy, 71 years (range: 47 - 92 years)	Disc. AE: Hepatotoxicity, Diarrhea...
150 mg 2 times / day steady, oral Recommended	unhealthy, adult	Other AEs: Hepatotoxicity, Diarrhea...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Arterial pressure NOS increased	all grades, 25%	350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)
Bilirubin increased	all grades, 25%	350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)
Chills	all grades, 25%	350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)
Constipation	all grades, 25%	350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)
Edema peripheral	all grades, 25%	350 mg 2 times / day multiple, oral Highest studied dose	unhealthy, 64 years (range: 32-91 years)

Showing 1 to 5 of 33 entries

Previous1 2 3 4 5 6 7Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:82701	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82701
ChemicalBook	CB32538915	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32538915
ChemicalBook	CB62638450	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB62638450
eMolecules	36516858	https://www.emolecules.com/cgi-bin/more?vid=36516858
MolPort	MolPort-016-633-355	https://www.molport.com/shop/molecule-link/MolPort-016-633-355

Showing 1 to 5 of 8 entries

Previous1 2Next

PubMed

Show entries

Title	Date	PubMed
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.	2014 Mar 13	24450857
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.	2014 May 29	24615776

Showing 1 to 2 of 2 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 150 mg taken orally, twice daily

Route of Administration: Oral

In Vitro Use Guide

Treatment of primary CLL cells (n =14) co-cultured with HS5 stromal cells with 100 nM idelalisib results in decreased AKT phosphorylation and inhibition of BCR mediated signaling pathways.

Substance Class	Chemical
Record UNII	YG57I8T5M0
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

idelalisib [INN]

Preferred Name

English

IDELALISIB

Official Name

English

CAL-101

Code

English

GS-1101

Code

English

4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(1H-PURIN-6-YLAMINO)PROPYL)-

Systematic Name

English

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Designated/Approved

FDA ORPHAN DRUG

405913

LYMPHOMA

EMA ASSESSMENT REPORTS

ZYDELIG (AUTHORIZED: LYMPHOMA, NON-HODGKIN)

Antineoplastic Protein Inhibitor

NCI_THESAURUS

C129825

Designated/Approved

FDA ORPHAN DRUG

405813

Other antineoplastic agents

WHO-ATC

L01XX47

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DB09054

PRIMARY

NDF-RT

N0000175082

PRIMARY

Kinase Inhibitors [MoA]

SMS_ID

100000151771

PRIMARY

RXCUI

1544460

PRIMARY

RxNorm

LACTMED

Idelalisib

PRIMARY

Showing 1 to 5 of 22 entries

Previous1 2 3 4 5Next

Show entries

Related Record

Type

Details


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					66DDF797LP

OATP-8

TRANSPORTER -> INHIBITOR

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:

84 % (average)


					JQ83GG8LT2

PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM

TARGET->WEAK INHIBITOR

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					W99Y3YHO0I

GS-563117

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA


					W99Y3YHO0I

GS-563117

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA


					8AY8QEH4JW

GS-563129

METABOLITE -> PARENT


					W99Y3YHO0I

GS-563117

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA


					W99Y3YHO0I

GS-563117

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					YG57I8T5M0

IDELALISIB

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Referenced Substance
blood-to-plasma ratio	PHARMACOKINETIC	0.7 (average)	`YG57I8T5M0` IDELALISIB

Volume of Distribution	PHARMACOKINETIC	23 LITERS (average)	`YG57I8T5M0` IDELALISIB

Tmax	PHARMACOKINETIC	1.5 hours [0.5 to 6] (average)	`YG57I8T5M0` IDELALISIB

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2